China Blood Product Industry Report, 2019-2025

Publisher Name :
Date: 20-Feb-2019
No. of pages: 169

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood products has been further opened. In 2018, the lot release volume of Chinese main blood products increased 13.5% year on year to 73.94 million bottles, of which the lot release volume of human albumin soared 13.8% year on year to 45.17 million bottles.

At present, Chinese blood products are still center on albumin, of which human albumin occupies a relatively high proportion. By the lot release volume, human albumin accounts for about 60%, followed by human immunoglobulin for intravenous injection with about 15%, human rabies immunoglobulin and tetanus immunoglobulin with more than 5% each.

The proportion of human fibrinogen, three special immunoglobulins, human prothrombin complex and coagulation factor VIII is relatively low, especially coagulation factor products, life-saving drugs for hemophilia patients, are often in shortage. The main reason is that the current utilization rate of plasma in China is low, and many companies are unable to produce such blood products. Therefore, China’s blood product industry still faces big problems: how to further raise the plasma collection volume, how to expand the production scale of various products, how to improve the resource utilization, and how to alleviate the tight supply

There are over 30 blood product manufacturers in a less concentrated industry in China. Among them, China Biologic Products, Hualan Biological Engineering, Shanghai RAAS Blood Products and Beijing Tiantan Biological Products are more competitive, as they have richer blood product lines and adequate supply of raw materials from plasma stations.

In the future, China’s blood product industry will see faster industry integration and higher concentration.

The report highlights the following:


  • Analysis on development of China blood product industry, including policies, status quo, market structure, supply & demand, market size and competitive landscape;

  • Analysis on market segments of China blood product industry, covering human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor VIII, hepatitis B human immunoglobulin, human immunoglobulin, human prothrombin complex, Tetanus Immunoglobulin, and Human Rabies Immunoglobulin;

  • Analysis on 13 blood product enterprises, including operation, revenue structure, gross margin, R & D investment, blood product business and development strategy;

  • Summary & forecast and trends

China Blood Product Industry Report, 2019-2025

Table of Contents

1. Overview of Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. Development of China Blood Product Industry
2.1 Related Policies
2.2 Status Quo
2.3 Market Structure
2.4 Market Supply and Demand
2.4.1 Supply
2.4.2 Demand
2.5 Market Size
2.6 Competition Pattern

3. Market Segments of China Blood Product Industry
3.1 Human Albumin
3.1.1 Development Status
3.1.2 Bid Price
3.1.3 Market Structure
3.1.4 Competition Pattern
3.1.5 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Development Status
3.2.2 Bid Price
3.2.3 Competition Pattern
3.2.4 Prospects
3.3 Coagulation Factor VIII
3.3.1 Development Status
3.3.2 Bid Price
3.3.3 Competition Pattern
3.3.4 Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Development Status
3.4.2 Bid Price
3.4.3 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Development Status
3.5.2 Bid Price
3.5.3 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Development Status
3.6.2 Bid Price
3.6.3 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Development Status
3.7.2 Bid Price
3.7.3 Competition Pattern
3.8 Human Rabies Immunoglobulin
3.8.1 Development Status
3.8.2 Bid Price
3.8.3 Competition Pattern

4. Major Enterprises
4.1 China Biologic Products (CBPO)
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Strucuture
4.1.4 Gross Margin
4.1.5 R&D Investment
4.1.6 Blood Products Business
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Shandong Taibang Biological Products Co., Ltd.
4.1.9 Xi'an Huitian Blood Products Co., Ltd.
4.2 Hualan Biological Engineering Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Strucuture
4.2.4 Gross Margin
4.2.5 R&D Investment
4.2.6 Blood Products Business
4.2.7 Development Strategy
4.3 Shanghai RAAS Blood Products
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Strucuture
4.3.4 Gross Margin
4.3.5 R&D Investment
4.3.6 Blood Products Business
4.3.7 Development Strategy
4.4 Beijing Tiantan Biological Products
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Strucuture
4.4.4 Gross Margin
4.4.5 R&D Investment
4.4.6 Blood Products Business
4.4.7 Chengdu Rongsheng
4.5 Zhenxing Biopharmaceutical & Chemical
4.5.1 Profile
4.5.2 Operation
4.5.3 Gross Margin
4.5.4 R&D Investment
4.5.5 Blood Products Business
4.5.6 Development Strategy
4.6 Jiangxi Boya Bio-Pharmaceutical
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D Investment
4.6.6 Blood Products Business
4.6.7 Development Strategy
4.7 Weiguang Biological Products
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Strucuture
4.7.4 Gross Margin
4.7.5 R&D Investment
4.7.6 Blood Products Business
4.7.7 Development Strategy
4.8 Beijing Bohui Innovation Technology
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Strucuture
4.8.4 Gross Margin
4.8.5 R&D Investment
4.8.6 Blood Products Business
4.8.7 Development Strategy
4.9 Wuhan ZhongyuanRuide Biological Products
4.9.1 Profile
4.9.2 Operation
4.9.3 Blood Products Business
4.8 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.8.1 Profile
4.10.2 Blood Products Business
4.11 Shanxi Kangbao Biological Product
4.11.1 Profile
4.11.2 Blood Products Business
4.12 Green Cross China
4.12.1 Profile
4.12.2 Blood Products Business
4.13 Nanyue Biopharming Corporation Ltd.
4.13.1 Profile
4.13.2 Blood Products Business

5. Summary and Forecast
5.1 Summary
5.2 Development Trend
5.2.1 The Industry Continues to Boom
5.2.2 Industry Integration Speeds Up, Concentration Rises Further
5.2.3 Plasma Collection Volume and Number of Plasma Stations Determine the Status in the Industry
5.2.4 Plasma Volume Increases Progressively
5.2.5 Enterprises Make More Input in R&D of New Products to Sharpen Competitiveness
5.2.6 Comprehensive Utilization of Blood Plasma Gets a Further Rise
5.2.7 Downstream Demand Stimulates the Development of the Industry
5.2.8 Healthcare System Reform Deepens, Gradual Perfection of Medical Insurance System Favors the Development of the Industry

List of Charts

Basic Components of Blood
Plasma Protein Separation Procedure
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Comparison of Recombinant Blood Products in China and Overseas
Blood Product Industry Chain
Time Length of Plasma Collection and Separation Process
Comparison between Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs & Expenses
Production & Sales Cycle of Blood Products
Main Policies on China Blood Product Industry, 1989-2017
Development History of China Blood Product Industry
Comparison between China and the United States in Per Capita Consumption of Main Blood Products
Lot Release Volume of Major Blood Products in China, 2014-2018
Blood Product Structure in China (by Lot Release Volume), 2014-2018
Plasma Collection Policies in China vs. USA and European Countries
Per Capita Frequency of Plasma Donation and Plasma Collection Volume in China vs. Euro-America
Number of Plasma Collection Stations and YoY Growth Rate in China, 2008-2018
Plasma Station Approval of Major Blood Product Enterprises in China, 2014-2018
Plasma Collection Volume and YoY Growth Rate in China, 2008-2018
Comparison of Blood Products Listed in National Medical Insurance Catalogue: 2017vs2009
Plasma Supply and Demand in China, 2015-2025E
Comparison of Cap-lift Prices and Original Highest Retail Prices of Blood Products
Market Size of China Blood Product Industry, 2010-2018
Number of Plasma Stations and Plasma Volume of Major Blood Product Enterprises in China, As of Jan. 2019
Main Products of Major Blood Product Manufacturing Enterprises in China
Revenue of Major Blood Product Enterprises in China, 2013-2018
Net Income of Major Blood Product Enterprises in China, 2013-2018
Revenue from Blood Products Business of Major Blood Product Enterprises in China, 2013-2018
Market Share of China Blood Product Industry (by Enterprise), 2017
Market Share of China Blood Product Industry (by Enterprise), 2018
Lot Release Volume and YoY Growth Rate of Human Albumin in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Albumin, 2018Q4
Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2018
Market Share of Human Albumin in China (by Lot Release Volume), 2017
Market Share of Human Albumin in China (by Lot Release Volume), 2018
Lot Release Volume of Human Immunoglobulin for Intravenous Injection in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin (pH4) for Intravenous Injection, 2018Q4  
Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2017
Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2018
Comparison between China and the United States in Per Capita Consumption of Human Albumin and Human Immunoglobulin (pH4) for Intravenous Injection
Lot Release Volume of Blood Coagulation Factor VIII in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Coagulation Factor VIII, 2018Q4       
Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2017
Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2018
Comparison between China and the United States in Per Capita Consumption of Coagulation Factor VIII
Coagulation Factor VIII R&D Progress of Major Blood Product Enterprises in China     
Lot Release Volume of Hepatitis B Immunoglobulin in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Hepatitis B Immunoglobulin, 2018Q4
Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2017
Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2018
Lot Release Volume of Human Immunoglobulin in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin, 2018Q4  
Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2017
Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2018
Lot Release Volume of Human Prothrombin Complex in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Prothrombin Complex, 2018Q4
Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2017
Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2018
Lot Release Volume of Tetanus Immunoglobulin in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Tetanus Immunoglobulin, 2018Q4
Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2017
Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2018
Cases, Deaths and Mortality of Rabies in China, 2013-2018
Lot Release Volume of Human Rabies Immunoglobulin in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Rabies Immunoglobulin, 2018Q4      
Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2017
Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2018
Product Line of CBPO
Equity Structure of China Biologic Products Holdings
Revenue and Operating Income of CBPO, 2012-2018
Revenue Breakdown of CBPO (by Product), 2012-2018
Revenue Structure of CBPO (by Product), 2012-2018
Gross Margin of CBPO, 2012-2018
R&D Costs and % of Total Revenue of CBPO, 2012-2018
CBPO’s Products under Research and R&D Process by the end of 2017
Lot Release Volume of Blood Products of CBPO, 2016-2018
Main Plasma Collection Stations of Guizhou Taibang Biological Products as of Jan. 2019
Lot Release Volume of Blood Products of Guizhou Taibang Biological Products, 2016-2018
Ownership Structure of Shandong Taibang Biological Products
Main Plasma Collection Stations of Shandong Taibang Biological Products as of Jan. 2019
Lot Release Volume of Blood Products of Shandong Taibang Biological Products, 2016-2018
Ownership Structure of Xi'an Huitian Blood Products
Main Plasma Collection Stations of Xi'an Huitian Blood Products as of 2019
Lot Release Volume of Blood Products of Xi'an Huitian Blood Products, 2017-2018
Revenue and Net Income of Hualan Biological Engineering, 2013-2018
Revenue Breakdown of Hualan Biological Engineering (by Product), 2013-2018
Revenue Structure of Hualan Biological Engineering (by Product), 2013-2018
Gross Margin of Blood Products of Hualan Biological Engineering (by Product), 2013-2018
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2018
Category and Specification of Blood Products of Hualan Biological Engineering
Revenue of Blood Products of Hualan Biological Engineering, 2013-2018
Lot Release Volume of Blood Products of Hualan Biological Engineering, 2015-2018
Revenue and Net Income of Shanghai RAAS Blood Products, 2013-2018
Revenue Breakdown of Shanghai RAAS Blood Products (by Product), 2013-2018
Revenue Structure of Shanghai RAAS Blood Products (by Product), 2013-2018
Revenue Breakdown of Shanghai RAAS Blood Products (by Region), 2013-2018
Revenue Structure of Shanghai RAAS Blood Products (by Region), 2013-2018
Gross Margin of Shanghai RAAS Blood Products (by Product), 2013-2018
R&D Costs of Shanghai RAAS Blood Products, 2015-2018
Blood Products of Shanghai RAAS Blood Products and Its Subsidiaries
Revenue and Net Income of Tiantan Biological Products, 2013-2018
Revenue Breakdown of TIANTANBIO (by Product), 2013-2017
Revenue Structure of TIANTANBIO (by Product), 2013-2017
Gross Margin of TIANTANBIO (by Product), 2013-2017
R&D Costs and % of Total Revenue of TIANTANBIO, 2013-2018
R&D Input of Major Projects of TIANTANBIO, 2017
Progress of Major R&D Projects of TIANTANBIO, by the End of 2017
TIANTANBIO’s Major Blood Products Subsidiaries and Stake
Production and Sales of Main Blood Products of TIANTANBIO, 2017
Lot Release Volume of Main Blood Products of TIANTANBIO, 2015-2018
Revenue and Net Income of Chengdu Rongsheng Pharmaceutical, 2015-2018
Revenue and Net Income of Zhenxing Biopharmaceutical & Chemical, 2013-2018
Gross Margin of Zhenxing Biopharmaceutical & Chemical, 2013-2018
R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical & Chemical, 2013-2018
Revenue and Net Income of Shuanglin Bio-Pharmacy, 2014-2018
Production-use Plasma Volume of Guangdong Shuanglin Bio-Pharmacy, 2013-2018
Production, Inventory and Sales of Main Blood Products of Zhenxing Biopharmaceutical & Chemical, 2013-2017
Lot Release Volume of Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2015-2018
Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2013-2018
Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2017
Revenue Structure of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2017
Revenue from Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
Revenue Proportion of Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Product), 2013-2017
Gross Margin of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2013-2018
R&D Costs of Jiangxi Boya Bio-Pharmaceutical, 2013-2018
Production and Sales of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2016-2017
Lot Release Volume of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
Revenue and Net Income of Shenzhen Weiguang Biological Products, 2014-2018
Revenue Breakdown of Shenzhen Weiguang Biological Products (by Product), 2014-2018
Revenue Structure of Shenzhen Weiguang Biological Products (by Product), 2014-2018
Gross Margin of Shenzhen Weiguang Biological Products, 2014-2018
Gross Margin of Shenzhen Weiguang Biological Products (by Product), 2014-2018
R&D Costs and % of Total Revenue of Shenzhen Weiguang Biological Products, 2014-2018
Progress of Fundraising Projects of Shenzhen Weiguang Biological Products, as of 2018H1
Plasma Collection Volume of Shenzhen Weiguang Biological Products, 2014-2017
Production and Sales of Blood Products of Shenzhen Weiguang Biological Products, 2016-2017
Financial Data of Plasma Collection Stations of Shenzhen Weiguang Biological Products, 2017
Financial Data of Plasma Collection Stations of Shenzhen Weiguang Biological Products, 2018H1
Lot Release Volume of Blood Products of Shenzhen Weiguang Biological Products, 2016-2018
Revenue and Net Income of Beijing Bohui Innovation Technology, 2014-2018
Revenue Breakdown of Beijing Bohui Innovation Technology by Product, 2014-2018
Revenue Structure of Beijing Bohui Innovation Technology by Product, 2014-2018
Gross Margin of Beijing Bohui Innovation Technology by Product, 2014-2018
R&D Costs and % of Total Revenue of Beijing Bohui Innovation Technology, 2014-2018
Progress of Major Blood Product R&D Projects of Beijing Bohui Innovation Technology, 2018H1
Financials of Beijing Bohui Innovation Technology, 2017-2018
Lot Release Volume of Blood Products of Hebei Da’an Pharmaceutical, 2016-2018
Lot Release Volume of Blood Products of Guangdong Weilun Biological Pharmaceutical, 2016-2018
Development Course of Zhongyuan Ruide Biological Products
Financial Data of Zhongyuan Ruide, 2014-2017
Lot Release Volume of Blood Products of Zhongyuan Ruide Biological Products, 2016-2018
Development History of Sichuan Yuanda Shuyang Pharmaceutical
Specification of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical
Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2016-2018
Plasma Collection Stations of Shanxi Kangbao Biological Product as of Jan. 2019
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2016-2018
Plasma Collection Stations of Green Cross China as of Jan. 2019
Lot Release Volume of Blood Products of Green Cross China, 2016-2018
Lot Release Volume of Blood Products of Nanyue Biopharming, 2016-2018
Market Size of Blood Products in China, 2018-2025E
M&A Cases of Foreign Blood Product Companies
M&A Cases in China Blood Product Industry, 2008-2018
Plasma Collection Volume and YoY Change in China, 2018-2025E
R&D Investment of Major Chinese Blood Product Enterprises, 2013-2018

  • Global Cytokine Inhibitor Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Cytokine Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The development prospects of cytokine inhibitors are very broad, and these drugs have many medical applications and researches. Cytokine inhibitors can reduce The activity of cytokines, thereby inhibiting their role in immune responses and reducing The activation of immune cells and The occurrence o......
  • Global Microbial Growth Media Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    Microbial Growth Media is a nutrient component required by microorganisms, containing a variety of trace elements and trace elements, such as copper, iron, zinc, cobalt, manganese, etc. The global Microbial Growth Media market was valued at US$ 8007 million in 2023 and is anticipated to reach US$ 11530 million by 2030, witnessing a CAGR of 5.3% during The forecast period 2024-2030. The market for microbial growth media is essential in microbiology and biotechnology rese......
  • Global Protein Biochip Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 92
    Protein Biochip is a small Protein array used to quickly detect a large number of unknown proteins. It works in a similar way to a DNA chip. First, a large number of known proteins (such as monoclonal antibodies) are placed on a small substrate and then exposed to and reacted with The unknown protein sample. Due to The specific binding between The antigen and The antibody, it can finally be detected by means of laser. The global Protein Biochip market was valued at US$ 145 million i......
  • Global Isothermal Nucleic Acid Amplification Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 103
    Isothermal nucleic acid amplification is referred to isothermal nucleic acid amplification technology. And in this report, we get The statistics on reagents used in isothermal nucleic acid amplification technology. Nucleic acid isothermal amplification is a newer technique that amplifies DNA or RNA specific fragment from few copies to billion-fold copies under a one temperature condition, unlike PCR amplification that needs at least 30-35 thermal cycles to accomplish The reaction. T......
  • Global Microfluidics Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 134
    According to our LPI (LP Information) latest study, the global Microfluidics market size was valued at US$ 3118.7 million in 2023. With growing demand in downstream market, the Microfluidics is forecast to a readjusted size of US$ 7707.1 million by 2030 with a CAGR of 13.8% during review period. The research report highlights the growth potential of the global Microfluidics market. Microfluidics are expected to show stable growth in the future market. However, product differentiation, re......
  • Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 122
    According to our LPI (LP Information) latest study, the global Isothermal Nucleic Acid Amplification Technology (INAAT) market size was valued at US$ 6141.3 million in 2023. With growing demand in downstream market, the Isothermal Nucleic Acid Amplification Technology (INAAT) is forecast to a readjusted size of US$ 11250 million by 2030 with a CAGR of 9.0% during review period. The research report highlights the growth potential of the global Isothermal Nucleic Acid Amplification Technol......
  • Global Cytokines Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 119
    According to our LPI (LP Information) latest study, the global Cytokines market size was valued at US$ 203730 million in 2023. With growing demand in downstream market, the Cytokines is forecast to a readjusted size of US$ 611910 million by 2030 with a CAGR of 17.0% during review period. The research report highlights the growth potential of the global Cytokines market. Cytokines are expected to show stable growth in the future market. However, product differentiation, reducing costs, an......
  • Global Western Blot Imagers Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 94
    According to our LPI (LP Information) latest study, the global Western Blot Imagers market size was valued at US$ 406 million in 2023. With growing demand in downstream market, the Western Blot Imagers is forecast to a readjusted size of US$ 578.4 million by 2030 with a CAGR of 5.2% during review period. The research report highlights the growth potential of the global Western Blot Imagers market. Western Blot Imagers are expected to show stable growth in the future market. However, prod......
  • Global Procalcitonin Antibody Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 125
    According to our LPI (LP Information) latest study, the global Procalcitonin Antibody market size was valued at US$ million in 2023. With growing demand in downstream market, the Procalcitonin Antibody is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Procalcitonin Antibody market. Procalcitonin Antibody are expected to show stable growth in the future market. However, product di......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs